Cabozantinib for Patients With Recurrent or Progressive Meningioma (NCT05425004)

🧪 Interventions in This Study

• Cabozantinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (3 Sites)

• Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
• Memorial Sloan Kettering Cancer Center — New York, New York
• Vanderbilt University Medical Center — Nashville, Tennessee

📞 Contact the Study Coordinator

Phone: (786) 596-2000

Email: RupeshK@baptisthealth.net

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Meningioma

• Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas — Chicago, Illinois
• A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas — Boston, Massachusetts
• Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma — New York, New York
• DOTATATE PET for Meningioma Radiation Planning — Vancouver, British Columbia
• Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC — New York, New York
• A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma — San Francisco, California

Explore by condition: All Meningioma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.